Oral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventions
GLP-1 receptor agonists like semaglutide and tirzepatide do not appear to increase the risk of oral health issues broadly, but dry mouth may be a concern associated with weight loss.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
This study evaluated oral health outcomes in 184,582 users of semaglutide or tirzepatide over a 12-month period. The research found that 8.69% of GLP-1 users developed at least one new oral-health condition, with dry mouth being the most frequent at 5.29%. Compared to matched users of other anti-diabetic therapies, GLP-1 users had a lower incidence of various oral-health conditions.
Abstract
Semaglutide and tirzepatide are increasingly used for obesity and diabetes, producing substantial changes in appetite, dietary intake, body weight, glycemic control, and gastrointestinal physiology that could plausibly influence oral health. Reports of xerostomia and dental complications have emerged, but population-scale risk of new-onset oral disease remains unclear. Using de-identified electronic health records from a federated system of 29 million patients, we evaluated 15 oral and dental conditions over a 12-month follow-up period in 184,582 semaglutide or tirzepatide users after excluding patients with substantial pre-existing oral-health burden. GLP-1 receptor agonist users were propensity-score matched to patients initiating other anti-diabetic therapies (42,093 pairs) and undergoing bariatric surgery (15,793 pairs) and comparisons were performed based on structured diagnosis codes and natural language processing-derived phenotypes from clinical notes. During follow-up, 8.69% of GLP-1 users developed at least one newly documented oral-health condition, with dry mouth most frequent (5.29%). Compared with matched users of other anti-diabetic therapies, GLP-1 users had lower incidence of any oral-health condition (RR 0.74, 95% CI 0.71–0.77), dental caries (RR 0.47, 0.40–0.56), and periodontitis (RR 0.50, 0.40–0.61). Dental plaque/calculus was the only condition with higher incidence (RR 1.27, 1.02–1.56). Similar trends were observed versus bariatric surgery (any oral-health condition: RR 0.80, 0.75–0.86). Dry-mouth incidence increased with greater treatment-associated weight loss (P<0.001). Overall, semaglutide or tirzepatide initiation was not associated with broadly increased oral-health risk, although dry mouth may represent a weight-loss-associated phenotype warranting further study.
Background
The study appears to address the impact of GLP1 receptor agonists, such as Semaglutide, on oral health outcomes compared to other metabolic interventions. This is a relevant area of research as GLP1 receptor agonists are primarily used for metabolic conditions like diabetes and obesity, and their effects on oral health are not well-documented. Understanding these effects could provide insights into the broader health implications of these treatments.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Without the abstract, it is unclear how the findings of this study compare to existing literature or whether the effects observed are clinically meaningful. The lack of detailed information limits the ability to assess potential confounds or the implications for practice.
Limitations
- abstract not available
- preprint status
- unknown study design
- unknown sample size
- unknown outcome measures